BioNTech (BNTX) vs Madrigal Pharmaceuticals (MDGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Madrigal Pharmaceuticals (MDGL) has outperformed BioNTech (BNTX) over the past year, gaining 10.1% versus a loss of 7.2%. Over five years, MDGL leads with a +447.5% price change compared with -60.9% for BNTX. BioNTech is the larger company by market cap ($24.36 billion vs $10.90 billion), about 2.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTX | MDGL |
|---|---|---|
| Share price | $96.96 | $471.75 |
| Market cap | $24.36B | $10.90B |
| 1-day change | +5.32% | -1.08% |
| YTD return | +1.85% | -18.99% |
| 1-year return | -7.20% | +10.14% |
| 5-year return | -60.85% | +447.46% |
| Forward P/E | — | 49.01 |
| EPS (TTM) | $-7.83 | $-12.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $958.40M |
| Revenue growth (YoY) | — | +432.05% |
| Net income (latest FY) | — | $-288.28M |
| Operating margin | — | -31.31% |
| Net margin | — | -30.08% |
| 52-week high | $124.00 | $615.00 |
| 52-week low | $79.52 | $393.61 |
| Distance from 52-week high | -21.81% | -23.29% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +19.85% | +44.59% |
| Average volume | 1.17M | 289.24K |
| Shares outstanding | 251.20M | 23.10M |
| Employees | 7,807 | 915 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BioNTech is about 2.2 times larger than Madrigal Pharmaceuticals by market value ($24.36B vs $10.90B).
- MDGL has outperformed BNTX by 17.3 percentage points over the past year.
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
About Madrigal Pharmaceuticals
MDGL stock →Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
Health Care · Biotechnology: Pharmaceutical Preparations · 915 employees
BNTX vs MDGL FAQ
Which is bigger, BioNTech or Madrigal Pharmaceuticals?
BioNTech (BNTX) is larger, with a market capitalization of $24.36B compared with $10.90B for Madrigal Pharmaceuticals (MDGL).
Which stock has performed better over the past year, BNTX or MDGL?
MDGL returned +10.14% over the past 12 months, compared with -7.20% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Are BioNTech and Madrigal Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for BioNTech and Biotechnology: Pharmaceutical Preparations for Madrigal Pharmaceuticals.